

Rev03
 Update: Aug,08,2025

DATASHEET


IL-18BP, His, Mouse

Cat. No.: Z06194


Product Introduction

Species	Mouse
Protein Construction	<div style="display: flex; align-items: center; justify-content: center;"> <div style="background-color: #0056b3; color: white; padding: 5px; text-align: center;"> IL-18BP (Thr29-Ala193)_x000D_ Accession # Q9Z0M9 </div> <div style="background-color: #76923c; color: white; padding: 5px; text-align: center; margin-left: 10px;"> His </div> </div> <div style="display: flex; justify-content: space-around; margin-top: 5px; font-size: small;"> N-term C-term </div>
Purity	> 95% as determined by Bis-Tris PAGE
Endotoxin Level	Less than 1EU per µg by the LAL method.
Biological Activity	Measured by its binding ability in a functional ELISA. Immobilized IL-18BP, His, Mouse at 1µg/ml (100µl/well) on the plate can bind Biotinylated IL18, No Tag. Test result was comparable to standard batch
Expression System	HEK293
Theoretical Molecular Weight	19.1 kDa
Apparent Molecular Weight	Due to glycosylation, the protein migrates to 45-65 kDa based on Bis-Tris PAGE result.
Formulation	Lyophilized from 0.22µm filtered solution in PBS (pH 7.4).
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability	Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.


Examples



IL-18BP, His, Mouse on Bis-Tris PAGE under reduced condition.
 The purity is greater than 95%.



IL-18BP, His, Mouse, His Tag captured on CM5 Chip via anti-his antibody can bind Human IL-18, No Tag with an affinity constant of 0.86 nM as determined in SPR assay (Biacore T200).



Immobilized IL-18BP, His, Mouse, His Tag at 1 µg/ml (100 µl/well) on the plate. Dose response curve for Biotinylated Human IL-18, No Tag with the EC₅₀ of 21.5 ng/ml determined by ELISA.

Background

Target Background : Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer, components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice.

Synonyms : IL-18BP; Igifbp

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.

Manufacturer: Nanjing GenScript Biotech Co., Ltd. No. 28Yongxi Road, Jiangning District, Nanjing, Jiangsu, China